Zobrazeno 1 - 10
of 592
pro vyhledávání: '"V. Santi"'
Publikováno v:
Ilomata International Journal of Tax and Accounting, Vol 5, Iss 1, Pp 180-201 (2024)
Financial distress is a situation that arises when a company has an unstable financial situation. If this condition continues, it will impact the company’s bankruptcy. This research aims to determine the influence of Good Corporate Governance, Firm
Externí odkaz:
https://doaj.org/article/7cc8aecb752e43c3902e7ef9b0c5e645
Publikováno v:
Dinamisia, Vol 5, Iss 6, Pp 1507-1513 (2021)
Pandemi Covid-19 berdampak besar dalam berbagai aspek kehidupan, termasuk aspek ekonomi. Berbagai jenis usaha dan industri, khususnya yang berskala mikro dan kecil harus berstrategi menekan biaya operasional agar mampu bertahan di masa adaptasi kebia
Externí odkaz:
https://doaj.org/article/2bdb6553eb7b4f9cb4d3228b486b4738
Publikováno v:
Cancer Research Communications. 3:908-916
Exatecan (Exa) is a very potent inhibitor of topoisomerase I and anticancer agent. It has been intensively studied as a single agent, a large macromolecular conjugate and as the payload component of antigen-dependent antibody–drug conjugates. The c
Autor:
Niranjan Meher, Gary W. Ashley, Anil P. Bidkar, Suchi Dhrona, Cyril Fong, Shaun D. Fontaine, Denis R. Beckford Vera, David M. Wilson, Youngho Seo, Daniel V. Santi, Henry F. VanBrocklin, Robert R. Flavell
Publikováno v:
ACS applied materials & interfaces, vol 14, iss 45
Tumoral uptake of large-size nanoparticles is mediated by the enhanced permeability and retention (EPR) effect, with variable accumulation and heterogenous tumor tissue penetration depending on the tumor phenotype. The performance of nanocarriers via
Synergy of PEG-Exa 3A and the ATRi VX-970.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f624bc3b94197d01f4ed5c5435648a
https://doi.org/10.1158/2767-9764.23144659
https://doi.org/10.1158/2767-9764.23144659
Exatecan (Exa) is a very potent inhibitor of topoisomerase I and anticancer agent. It has been intensively studied as a single agent, a large macromolecular conjugate and as the payload component of antigen-dependent antibody–drug conjugates. The c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7729fa7fa98ce69ea2bbe3df77734cde
https://doi.org/10.1158/2767-9764.c.6620331.v2
https://doi.org/10.1158/2767-9764.c.6620331.v2
Pharmacokinetic profile of PEG-Exa conjugates 3A and 3B. A, C versus t plots after intraperitoneal administration of 7.5 μmol/kg 3A and 15 μmol/kg 3B to mice (n = 4/group); data for 3A normalized to 15 μmol/kg are also shown. Average C versus t cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a701773b853802adc2665c064f350e2b
https://doi.org/10.1158/2767-9764.23144683
https://doi.org/10.1158/2767-9764.23144683
Body weights of mice treated with PEG-Exa combinations with TLZ or VX970.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3d288dc7c4c858799304dede55776fa
https://doi.org/10.1158/2767-9764.23144668
https://doi.org/10.1158/2767-9764.23144668
PEG-Exa combinations with TLZ or VX970. A, Median relative tumor volume ± interquartile range versus time for PEG-Exa, TLZ, or a combination. The starting tumor volume for all groups was 156 ± 57 mm3. Mice (N = 6/group) received a single intraperit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b8e24790ea97aa81460256baeff2616
https://doi.org/10.1158/2767-9764.23144677
https://doi.org/10.1158/2767-9764.23144677
SCHEME 2 from A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7480fe1ed88ed895e888cc405c5e4e1f
https://doi.org/10.1158/2767-9764.23144674
https://doi.org/10.1158/2767-9764.23144674